ProQR Therapeutics N.V. PRQR
$ 4.07
2.26%
Annual report 2023
added 11-09-2024
ProQR Therapeutics N.V. Balance Sheet 2011-2024 | PRQR
Annual Balance Sheet ProQR Therapeutics N.V.
2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-171 M | -58.4 M | -98.7 M | -96.2 M | -40.9 M | -53.5 M | -90 M | -110 M | -589 K | -153 K | - | ||
Long Term Debt |
- | - | 14.7 M | 16.2 M | 12.7 M | 9.39 M | 5.28 M | 5.7 M | 4.82 M | 2.81 M | 943 K | 96 K | - |
Long Term Debt Current |
1.61 M | 1.39 M | 1.53 M | 1.26 M | 508 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 31.9 M | 12.7 M | 9.39 M | 5.28 M | 5.7 M | 4.82 M | 2.83 M | 991 K | 96 K | - |
Total Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
96.5 M | 106 M | 96.4 M | 42.2 M | 23.7 M | 17.5 M | 13.8 M | 12.4 M | 10.3 M | 5.84 M | 4.59 M | 239 K | - |
Deferred Revenue |
- | - | - | 700 K | 711 K | 545 K | 347 K | - | 144 K | - | - | - | - |
Retained Earnings |
- | - | - | -258 M | -212 M | -155 M | -119 M | -75.7 M | -36.6 M | -15.8 M | -3.67 M | -418 K | - |
Total Assets |
138 M | 171 M | 210 M | 98.7 M | 118 M | 110 M | 53.1 M | 65.5 M | 100 M | 115 M | 4.5 M | 338 K | - |
Cash and Cash Equivalents |
119 M | 94.8 M | 188 M | 75.8 M | 112 M | 106 M | 48.1 M | 59.2 M | 94.9 M | - | - | - | - |
Book Value |
41.4 M | 65.1 M | 113 M | 56.5 M | 93.8 M | 92.7 M | 39.3 M | 53.1 M | 89.8 M | 109 M | -89 K | 99 K | - |
Total Shareholders Equity |
- | - | 113 M | 56.5 M | 93.8 M | 92.7 M | 39.3 M | 53.1 M | 89.8 M | - | - | - | - |
All numbers in EUR currency
Quarterly Balance Sheet ProQR Therapeutics N.V.
2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 14.4 M | 14.7 M | 15.1 M | 15.5 M | - | 15.7 M | 14.7 M | - | - | - | - | 609 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 68.8 M | - | - | - | 31.9 M | - | - | - | 12.7 M | - | - | - | 9.39 M | - | - | - | 5.28 M | - | - | - | 5.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | 90 M | 96.4 M | 67.3 M | 44.8 M | - | 42.2 M | 42.1 M | 13.9 M | 22.3 M | 23.7 M | 21.6 M | 20 M | - | 17.5 M | - | 14.8 M | - | 13.8 M | - | - | - | 12.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | - | -318 M | - | - | - | -258 M | - | - | - | -212 M | - | - | - | -155 M | - | - | - | -119 M | - | - | - | -75.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | 190 M | 210 M | 195 M | 162 M | - | 98.7 M | 110 M | 93.5 M | 104 M | 118 M | 81.1 M | 90.3 M | - | 110 M | - | 37.5 M | - | 53.1 M | - | - | - | 65.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | 168 M | 188 M | 156 M | 139 M | 67.9 M | 75.8 M | 88.8 M | 87.1 M | 98.1 M | 112 M | 74.8 M | 82.5 M | 94.1 M | 106 M | 114 M | 33 M | 38 M | 48.1 M | - | 42.3 M | 52.1 M | 59.2 M | - | - | - | 94.9 M | - | - | - | 113 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | 100 M | 113 M | 128 M | 118 M | - | 56.5 M | 68.1 M | 79.6 M | 81.4 M | 93.8 M | 59.4 M | 70.2 M | - | 92.7 M | - | 22.7 M | - | 39.3 M | - | - | - | 53.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | 100 M | 113 M | 128 M | 118 M | 49.2 M | 56.5 M | 68.1 M | 79.6 M | 81.4 M | 93.8 M | 59.4 M | 70.2 M | 80.8 M | 92.7 M | 102 M | 22.7 M | - | 39.3 M | - | 36.8 M | - | 53.1 M | - | - | - | 89.8 M | - | - | - | 109 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency